File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

TitleOverview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast
Authors
Issue Date2010
PublisherOxford University Press. The Journal's web site is located at http://jncicancerspectrum.oxfordjournals.org/
Citation
Journal of the National Cancer Institute, 2010, v. 2010 n. 41, p. 162-177 How to Cite?
AbstractIndividual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. The proportional reduction in ipsilateral breast events was greater in older than in younger women (2P < .0004 for difference between proportional reductions; 10-year absolute risks: 18.5% vs 29.1% at ages <50 years, 10.8% vs 27.8% at ages >/= 50 years) but did not differ significantly according to any other available factor. Even for women with negative margins and small low-grade tumors, the absolute reduction in the 10-year risk of ipsilateral breast events was 18.0% (SE 5.5, 12.1% vs 30.1%, 2P = .002). After 10 years of follow-up, there was, however, no significant effect on breast cancer mortality, mortality from causes other than breast cancer, or all-cause mortality.
Persistent Identifierhttp://hdl.handle.net/10722/139113
ISSN
2015 Impact Factor: 11.37
2015 SCImago Journal Rankings: 6.192

 

DC FieldValueLanguage
dc.contributor.authorKwong, DLWen_US
dc.contributor.authorEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG)-
dc.date.accessioned2011-09-23T05:45:08Z-
dc.date.available2011-09-23T05:45:08Z-
dc.date.issued2010en_US
dc.identifier.citationJournal of the National Cancer Institute, 2010, v. 2010 n. 41, p. 162-177en_US
dc.identifier.issn0027-8874-
dc.identifier.urihttp://hdl.handle.net/10722/139113-
dc.description.abstractIndividual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. The proportional reduction in ipsilateral breast events was greater in older than in younger women (2P < .0004 for difference between proportional reductions; 10-year absolute risks: 18.5% vs 29.1% at ages <50 years, 10.8% vs 27.8% at ages >/= 50 years) but did not differ significantly according to any other available factor. Even for women with negative margins and small low-grade tumors, the absolute reduction in the 10-year risk of ipsilateral breast events was 18.0% (SE 5.5, 12.1% vs 30.1%, 2P = .002). After 10 years of follow-up, there was, however, no significant effect on breast cancer mortality, mortality from causes other than breast cancer, or all-cause mortality.-
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://jncicancerspectrum.oxfordjournals.org/-
dc.relation.ispartofJournal of the National Cancer Instituteen_US
dc.subject.meshBreast Neoplasms - drug therapy - radiotherapy - surgery-
dc.subject.meshCarcinoma, Intraductal, Noninfiltrating - drug therapy - radiotherapy - surgery-
dc.subject.meshMulticenter Studies as Topic - statistics and numerical data-
dc.subject.meshRadiotherapy, Adjuvant - statistics and numerical data-
dc.subject.meshRandomized Controlled Trials as Topic - statistics and numerical data-
dc.titleOverview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breasten_US
dc.typeArticleen_US
dc.identifier.emailKwong, DLW: dlwkwong@hkucc.hku.hken_US
dc.identifier.authorityKwong, DLW=rp00414en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/jncimonographs/lgq039-
dc.identifier.pmid20956824-
dc.identifier.scopuseid_2-s2.0-78650717087-
dc.identifier.hkuros194751en_US
dc.identifier.volume2010en_US
dc.identifier.issue41en_US
dc.identifier.spage162en_US
dc.identifier.epage177en_US
dc.publisher.placeUnited Kingdom-
dc.identifier.citeulike8835666-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats